SinoMab BioScience Ltd (HKSE:03681) Share Price

Company Profile

Business description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Contact
No. 15 Science Park West Avenue
Units 303 and 305 to 307
Hong Kong Science Park, Pak Shek Kok
New Territories
Hong Kong
HKG
T: +852 34269833
https://www.sinomab.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
61

Recommended

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.

Matthew Dolgin, CFA | 20 October 2025

Shares plunged over 17% after reporting disappointing results.

Angus Hewitt, CFA | 20 October 2025

Growth outlook solid, but upside more than priced in.

Shaun Ler | 19 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,390.10	16.40	0.17%
CAC 40	8,243.94	37.87	0.46%
DAX 40	24,277.59	18.79	0.08%
Dow JONES (US)	46,737.93	31.35	0.07%
FTSE 100	9,429.81	26.24	0.28%
HKSE	26,027.55	168.72	0.65%
NASDAQ	22,961.94	28.61	-0.12%
Nikkei 225	49,316.06	130.56	0.27%
NZX 50 Index	13,377.85	32.89	0.25%
S&P 500	6,734.85	0.28	-0.00%
S&P/ASX 200	9,094.70	18.80	0.21%
SSE Composite Index	3,916.33	52.44	1.36%